Medical Devices; Orthopedic Devices; Classification of the Screw Sleeve Bone Fixation Device, 11293-11295 [2022-04154]
Download as PDF
Federal Register / Vol. 87, No. 40 / Tuesday, March 1, 2022 / Rules and Regulations
[FR Doc. 2022–04022 Filed 2–28–22; 8:45 a.m.]
BILLING CODE 4910–13–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 888
[Docket No. FDA–2022–N–0114]
Medical Devices; Orthopedic Devices;
Classification of the Screw Sleeve
Bone Fixation Device
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Final amendment; final order.
The Food and Drug
Administration (FDA, Agency, or we) is
classifying the screw sleeve bone
fixation device into class II (special
controls). The special controls that
apply to the device type are identified
in this order and will be part of the
codified language for the screw sleeve
bone fixation device’s classification. We
are taking this action because we have
determined that classifying the device
into class II (special controls) will
provide a reasonable assurance of safety
and effectiveness of the device. We
believe this action will also enhance
patients’ access to beneficial innovative
devices.
DATES:
This order is effective March 1, 2022.
The classification was applicable on
May 1, 2020.
FOR FURTHER INFORMATION CONTACT:
Jesse Muir, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 4508, Silver Spring,
MD 20993–0002, 240–402–6679,
Jesse.Muir@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
jspears on DSK121TN23PROD with RULES1
I. Background
Upon request, FDA has classified the
screw sleeve bone fixation device as
class II (special controls), which we
have determined will provide a
reasonable assurance of safety and
effectiveness. In addition, we believe
this action will enhance patients’ access
to beneficial innovation, by placing the
device into a lower device class than the
automatic class III assignment.
The automatic assignment of class III
occurs by operation of law and without
any action by FDA, regardless of the
level of risk posed by the new device.
Any device that was not in commercial
distribution before May 28, 1976, is
automatically classified as, and remains
VerDate Sep<11>2014
16:32 Feb 28, 2022
Jkt 256001
within, class III and requires premarket
approval unless and until FDA takes an
action to classify or reclassify the device
(see 21 U.S.C. 360c(f)(1)). We refer to
these devices as ‘‘postamendments
devices’’ because they were not in
commercial distribution prior to the
date of enactment of the Medical Device
Amendments of 1976, which amended
the Federal Food, Drug, and Cosmetic
Act (FD&C Act).
FDA may take a variety of actions in
appropriate circumstances to classify or
reclassify a device into class I or II. We
may issue an order finding a new device
to be substantially equivalent under
section 513(i) of the FD&C Act (21
U.S.C. 360c(i)) to a predicate device that
does not require premarket approval.
We determine whether a new device is
substantially equivalent to a predicate
device by means of the procedures for
premarket notification under section
510(k) of the FD&C Act (21 U.S.C.
360(k)) and part 807 (21 CFR part 807).
FDA may also classify a device
through ‘‘De Novo’’ classification, a
common name for the process
authorized under section 513(f)(2) of the
FD&C Act. Section 207 of the Food and
Drug Administration Modernization Act
of 1997 (Pub. L. 105–115) established
the first procedure for De Novo
classification. Section 607 of the Food
and Drug Administration Safety and
Innovation Act (Pub. L. 112–144)
modified the De Novo application
process by adding a second procedure.
A device sponsor may utilize either
procedure for De Novo classification.
Under the first procedure, the person
submits a 510(k) for a device that has
not previously been classified. After
receiving an order from FDA classifying
the device into class III under section
513(f)(1) of the FD&C Act, the person
then requests a classification under
section 513(f)(2).
Under the second procedure, rather
than first submitting a 510(k) and then
a request for classification, if the person
determines that there is no legally
marketed device upon which to base a
determination of substantial
equivalence, that person requests a
classification under section 513(f)(2) of
the FD&C Act.
Under either procedure for De Novo
classification, FDA is required to
classify the device by written order
within 120 days. The classification will
be according to the criteria under
section 513(a)(1) of the FD&C Act.
Although the device was automatically
placed within class III, the De Novo
classification is considered to be the
initial classification of the device.
When FDA classifies a device into
class I or II via the De Novo process, the
PO 00000
Frm 00019
Fmt 4700
Sfmt 4700
11293
device can serve as a predicate for
future devices of that type, including for
510(k)s (see section 513(f)(2)(B)(i) of the
FD&C Act). As a result, other device
sponsors do not have to submit a De
Novo request or premarket approval
application to market a substantially
equivalent device (see section 513(i) of
the FD&C Act, defining ‘‘substantial
equivalence’’). Instead, sponsors can use
the less-burdensome 510(k) process,
when necessary, to market their device.
II. De Novo Classification
On December 13, 2018, FDA received
Woven Orthopedic Technologies, LLC’s
request for De Novo classification of the
OGmend® Implant System. FDA
reviewed the request in order to classify
the device under the criteria for
classification set forth in section
513(a)(1) of the FD&C Act.
We classify devices into class II if
general controls by themselves are
insufficient to provide reasonable
assurance of safety and effectiveness,
but there is sufficient information to
establish special controls that, in
combination with the general controls,
provide reasonable assurance of the
safety and effectiveness of the device for
its intended use (see 21 U.S.C.
360c(a)(1)(B)). After review of the
information submitted in the request,
we determined that the device can be
classified into class II with the
establishment of special controls. FDA
has determined that these special
controls, in addition to the general
controls, will provide reasonable
assurance of the safety and effectiveness
of the device.
Therefore, on May 1, 2020, FDA
issued an order to the requester
classifying the device into class II. In
this final order, FDA is codifying the
classification of the device by adding 21
CFR 888.3043.1 We have named the
generic type of device ‘‘screw sleeve
bone fixation device,’’ and it is intended
to be implanted in conjunction with a
non-resorbable, metallic bone screw
where the screw has lost purchase due
to loosening, backout, or breakage. The
device fits between the screw threads
and surrounding bone and provides
increased surface area to create an
1 FDA notes that the ‘‘ACTION’’ caption for this
final order is styled as ‘‘Final amendment; final
order,’’ rather than ‘‘Final order.’’ Beginning in
December 2019, this editorial change was made to
indicate that the document ‘‘amends’’ the Code of
Federal Regulations. The change was made in
accordance with the Office of Federal Register’s
(OFR) interpretations of the Federal Register Act (44
U.S.C. chapter 15), its implementing regulations (1
CFR 5.9 and parts 21 and 22), and the Document
Drafting Handbook.
E:\FR\FM\01MRR1.SGM
01MRR1
11294
Federal Register / Vol. 87, No. 40 / Tuesday, March 1, 2022 / Rules and Regulations
interference fit to restore stability of the
implant construct.
FDA has identified the following risks
to health associated specifically with
this type of device and the measures
required to mitigate these risks in table
1.
TABLE 1—SCREW SLEEVE BONE FIXATION DEVICE RISKS AND MITIGATION MEASURES
Identified risks
Mitigation measures
Loss of function/mechanical integrity resulting from:
D Device malposition.
D Device breakage.
D Damage to screw during insertion.
D Deterioration due to aging.
D Insufficient restoration of screw fixation.
Revision ....................................................................................................
In vivo performance testing; Non-clinical performance testing; Shelf life
testing; and Labeling.
Adverse tissue reaction ............................................................................
Infection ....................................................................................................
Febrile response due to endotoxins .........................................................
FDA has determined that special
controls, in combination with the
general controls, address these risks to
health and provide reasonable assurance
of safety and effectiveness. For a device
to fall within this classification, and
thus avoid automatic classification in
class III, it would have to comply with
the special controls named in this final
order. The necessary special controls
appear in the regulation codified by this
order. We encourage sponsors to consult
with us if they wish to use a non-animal
testing method that they believe is
suitable, adequate, validated, and
feasible. We will consider if such an
alternative method could be assessed for
equivalency to an animal test method.
This device is subject to premarket
notification requirements under section
510(k) of the FD&C Act.
jspears on DSK121TN23PROD with RULES1
III. Analysis of Environmental Impact
The Agency has determined under 21
CFR 25.34(b) that this action is of a type
that does not individually or
cumulatively have a significant effect on
the human environment. Therefore,
neither an environmental assessment
nor an environmental impact statement
is required.
IV. Paperwork Reduction Act of 1995
This final order establishes special
controls that refer to previously
approved collections of information
found in other FDA regulations and
guidance. These collections of
information are subject to review by the
Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501–3521). The
collections of information in 21 CFR
part 860, subpart D, regarding De Novo
classification have been approved under
OMB control number 0910–0844; the
collections of information in 21 CFR
part 814, subparts A through E,
VerDate Sep<11>2014
16:32 Feb 28, 2022
Jkt 256001
In vivo performance testing; Non-clinical performance testing; and Labeling.
Biocompatibility evaluation; In vivo performance testing; Non-clinical
performance testing; and Labeling.
Sterilization validation; and Shelf life testing.
Pyrogenicity testing.
regarding premarket approval, have
been approved under OMB control
number 0910–0231; the collections of
information in part 807, subpart E,
regarding premarket notification
submissions, have been approved under
OMB control number 0910–0120; the
collections of information in 21 CFR
part 820, regarding quality system
regulation, have been approved under
OMB control number 0910–0073; and
the collections of information in 21 CFR
part 801, regarding labeling, have been
approved under OMB control number
0910–0485.
List of Subjects in 21 CFR Part 888
Medical devices.
Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs, 21 CFR part 888 is
amended as follows:
PART 888—ORTHOPEDIC DEVICES
1. The authority citation for part 888
continues to read as follows:
■
Authority: 21 U.S.C. 351, 360, 360c, 360e,
360j, 360l, 371.
2. Add § 888.3043 to subpart D to read
as follows:
■
§ 888.3043
device.
Screw sleeve bone fixation
(a) Identification. A screw sleeve bone
fixation device is intended to be
implanted in conjunction with a nonresorbable, metallic bone screw where
the screw has lost purchase due to
loosening, backout, or breakage. The
device fits between the screw threads
and surrounding bone and provides
increased surface area to create an
interference fit to restore stability of the
implant construct.
PO 00000
Frm 00020
Fmt 4700
Sfmt 4700
(b) Classification. Class II (special
controls). The special controls for this
device are:
(1) In vivo performance testing under
anticipated conditions of use must
demonstrate:
(i) The device provides sufficient
stability to allow for fracture healing;
and
(ii) A lack of adverse biologic
response to the implant through
histopathological and
histomorphometric assessment.
(2) Non-clinical performance testing
must demonstrate that the device
performs as intended under anticipated
conditions of use. Testing must:
(i) Assess the stability of the device in
a rescue screw scenario;
(ii) Demonstrate that the device can be
inserted and removed without damage
to the implant or associated hardware;
(iii) Demonstrate the device can
withstand dynamic loading without
device failure; and
(iv) Characterize wear particle
generation.
(3) The device must be demonstrated
to be biocompatible.
(4) The device must be demonstrated
to be non-pyrogenic.
(5) Performance data must
demonstrate the sterility of the device.
(6) Performance data must support the
labeled shelf life of the device by
demonstrating continued sterility,
package integrity, and device
functionality over the established shelf
life.
(7) Labeling must include:
(i) A detailed summary of the device
technical parameters;
(ii) Information describing all
materials of the device;
(iii) Instructions for use, including
device removal; and
(iv) A shelf life.
E:\FR\FM\01MRR1.SGM
01MRR1
Federal Register / Vol. 87, No. 40 / Tuesday, March 1, 2022 / Rules and Regulations
Dated: February 22, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022–04154 Filed 2–28–22; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 1141
[Docket No. FDA–2019–N–3065]
RIN 0910–AI39
Tobacco Products; Required Warnings
for Cigarette Packages and
Advertisements; Delayed Effective
Date
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Final rule; delay of effective
date.
As required by an order
issued by the U.S. District Court for the
Eastern District of Texas, this action
delays the effective date of the final rule
(‘‘Tobacco Products; Required Warnings
for Cigarette Packages and
Advertisements’’), which published on
March 18, 2020. The new effective date
is April 9, 2023.
DATES: The effective date of the rule
amending 21 CFR part 1141 published
at 85 FR 15638, March 18, 2020, and
delayed at 85 FR 32293, May 29, 2020;
86 FR 3793, January 15, 2021; 86 FR
36509, July 12, 2021; 86 FR 50855,
September 13, 2021; and 86 FR 70052,
December 9, 2021, is further delayed
until April 9, 2023.
FOR FURTHER INFORMATION CONTACT:
Courtney Smith, Office of Regulations,
Center for Tobacco Products, Food and
Drug Administration, Document Control
Center, 10903 New Hampshire Ave.,
Bldg. 71, Rm. G335, Silver Spring, MD
20993–0002, 1–877–287–1371, email:
CTPRegulations@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In the
Federal Register of March 18, 2020, the
Food and Drug Administration (FDA or
Agency) issued a final rule establishing
new cigarette health warnings for
cigarette packages and advertisements.
The final rule implements a provision of
the Family Smoking Prevention and
Tobacco Control Act (Tobacco Control
Act) (Pub. L. 111–31) that requires FDA
to issue regulations requiring color
graphics depicting the negative health
consequences of smoking to accompany
new textual warning label statements.
The Tobacco Control Act amends the
Federal Cigarette Labeling and
jspears on DSK121TN23PROD with RULES1
SUMMARY:
VerDate Sep<11>2014
16:32 Feb 28, 2022
Jkt 256001
Advertising Act of 1965 (Pub. L. 89–92)
to require each cigarette package and
advertisement to bear one of the new
required warnings. The final rule
specifies the 11 new textual warning
label statements and accompanying
color graphics. Pursuant to section
201(b) of the Tobacco Control Act, the
rule was published with an effective
date of June 18, 2021, 15 months after
the date of publication of the final rule.
On April 3, 2020, the final rule was
challenged in the U.S. District Court for
the Eastern District of Texas.1 On May
8, 2020, the court granted a joint motion
to govern proceedings in that case and
postpone the effective date of the final
rule by 120 days.2 On December 2, 2020,
the court granted a new motion by the
plaintiffs to postpone the effective date
of the final rule by an additional 90
days.3 On March 2, 2021, the court
granted another motion by the plaintiffs
to postpone the effective date of the
final rule by an additional 90 days.4 On
May 21, 2021, the court granted another
motion by the plaintiffs to postpone the
effective date of the final rule by an
additional 90 days.5 On August 18,
2021, the court issued an order to
postpone the effective date of the final
rule by an additional 90 days.6 On
November 12, 2021, the court issued
another order to postpone the effective
date of the final rule by an additional 90
days.7 On February 10, 2022, the court
issued another order to postpone the
effective date of the final rule by an
additional 90 days.8 The court ordered
that the new effective date of the final
rule is April 9, 2023. Pursuant to the
court order, any obligation to comply
with a deadline tied to the effective date
is similarly postponed, and those
obligations and deadlines are now tied
to the postponed effective date.
1 R.J. Reynolds Tobacco Co. et al. v. United States
Food and Drug Administration et al., No. 6:20–cv–
00176 (E.D. Tex. filed April 3, 2020).
2 R.J. Reynolds Tobacco Co., No. 6:20–cv–00176
(E.D. Tex. May 8, 2020) (order granting joint motion
and establishing schedule), Doc. No. 33.
3 R.J. Reynolds Tobacco Co., No. 6:20–cv–00176
(E.D. Tex. December 2, 2020) (order granting
Plaintiffs’ motion and postponing effective date),
Doc. No. 80.
4 R.J. Reynolds Tobacco Co., No. 6:20–cv–00176
(E.D. Tex. March 2, 2021) (order granting Plaintiffs’
motion and postponing effective date), Doc. No. 89.
5 R.J. Reynolds Tobacco Co., No. 6:20–cv–00176
(E.D. Tex. May 21, 2021) (order granting Plaintiffs’
motion and postponing effective date), Doc. No. 91.
6 R.J. Reynolds Tobacco Co., No. 6:20–cv–00176
(E.D. Tex. August 18, 2021) (order postponing
effective date), Doc. No. 92.
7 R.J. Reynolds Tobacco Co., No. 6:20–cv–00176
(E.D. Tex. November 12, 2021) (order postponing
effective date), Doc. No. 93.
8 R.J. Reynolds Tobacco Co., No. 6:20–cv–00176
(E.D. Tex. February 10, 2022) (order postponing
effective date), Doc. No. 94.
PO 00000
Frm 00021
Fmt 4700
Sfmt 4700
11295
To the extent that 5 U.S.C. 553 applies
to this action, the Agency’s
implementation of this action without
opportunity for public comment,
effective immediately upon publication
in the Federal Register, is based on the
good cause exception in 5 U.S.C.
553(b)(B). Seeking public comment is
impracticable, unnecessary, and
contrary to the public interest. The 90day postponement of the effective date,
until April 9, 2023, is required by court
order in accordance with the court’s
authority to postpone a rule’s effective
date pending judicial review (5 U.S.C.
705). Seeking prior public comment on
this postponement would have been
impracticable, as well as contrary to the
public interest in the orderly issuance
and implementation of regulations.
Dated: February 23, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022–04181 Filed 2–28–22; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF THE TREASURY
Internal Revenue Service
26 CFR Part 300
[TD 9962]
RIN 1545–BQ06
User Fees Relating to the Enrolled
Agent Special Enrollment Examination
and the Enrolled Retirement Plan
Agent Special Enrollment Examination
Internal Revenue Service (IRS),
Treasury.
ACTION: Final regulations.
AGENCY:
These final regulations amend
existing regulations relating to the user
fees for the special enrollment
examinations for enrolled agents and
enrolled retirement plan agents. The
final regulations increase the amount of
the user fee for each part of the special
enrollment examination for enrolled
agents (EA SEE). The final regulations
also remove the user fee for the special
enrollment examination for enrolled
retirement plan agents (ERPA SEE)
because the IRS no longer offers the
ERPA SEE or new enrollment as an
enrolled retirement plan agent. The final
regulations affect individuals taking the
EA SEE. The Independent Offices
Appropriation Act of 1952 authorizes
charging user fees.
DATES: Effective date: These regulations
are effective March 31, 2022.
Applicability date: For the date of
applicability, see § 300.4(d).
SUMMARY:
E:\FR\FM\01MRR1.SGM
01MRR1
Agencies
[Federal Register Volume 87, Number 40 (Tuesday, March 1, 2022)]
[Rules and Regulations]
[Pages 11293-11295]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-04154]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 888
[Docket No. FDA-2022-N-0114]
Medical Devices; Orthopedic Devices; Classification of the Screw
Sleeve Bone Fixation Device
AGENCY: Food and Drug Administration, HHS.
ACTION: Final amendment; final order.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is
classifying the screw sleeve bone fixation device into class II
(special controls). The special controls that apply to the device type
are identified in this order and will be part of the codified language
for the screw sleeve bone fixation device's classification. We are
taking this action because we have determined that classifying the
device into class II (special controls) will provide a reasonable
assurance of safety and effectiveness of the device. We believe this
action will also enhance patients' access to beneficial innovative
devices.
DATES:
This order is effective March 1, 2022. The classification was
applicable on May 1, 2020.
FOR FURTHER INFORMATION CONTACT: Jesse Muir, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 4508, Silver Spring, MD 20993-0002, 240-402-6679,
[email protected].
SUPPLEMENTARY INFORMATION:
I. Background
Upon request, FDA has classified the screw sleeve bone fixation
device as class II (special controls), which we have determined will
provide a reasonable assurance of safety and effectiveness. In
addition, we believe this action will enhance patients' access to
beneficial innovation, by placing the device into a lower device class
than the automatic class III assignment.
The automatic assignment of class III occurs by operation of law
and without any action by FDA, regardless of the level of risk posed by
the new device. Any device that was not in commercial distribution
before May 28, 1976, is automatically classified as, and remains
within, class III and requires premarket approval unless and until FDA
takes an action to classify or reclassify the device (see 21 U.S.C.
360c(f)(1)). We refer to these devices as ``postamendments devices''
because they were not in commercial distribution prior to the date of
enactment of the Medical Device Amendments of 1976, which amended the
Federal Food, Drug, and Cosmetic Act (FD&C Act).
FDA may take a variety of actions in appropriate circumstances to
classify or reclassify a device into class I or II. We may issue an
order finding a new device to be substantially equivalent under section
513(i) of the FD&C Act (21 U.S.C. 360c(i)) to a predicate device that
does not require premarket approval. We determine whether a new device
is substantially equivalent to a predicate device by means of the
procedures for premarket notification under section 510(k) of the FD&C
Act (21 U.S.C. 360(k)) and part 807 (21 CFR part 807).
FDA may also classify a device through ``De Novo'' classification,
a common name for the process authorized under section 513(f)(2) of the
FD&C Act. Section 207 of the Food and Drug Administration Modernization
Act of 1997 (Pub. L. 105-115) established the first procedure for De
Novo classification. Section 607 of the Food and Drug Administration
Safety and Innovation Act (Pub. L. 112-144) modified the De Novo
application process by adding a second procedure. A device sponsor may
utilize either procedure for De Novo classification.
Under the first procedure, the person submits a 510(k) for a device
that has not previously been classified. After receiving an order from
FDA classifying the device into class III under section 513(f)(1) of
the FD&C Act, the person then requests a classification under section
513(f)(2).
Under the second procedure, rather than first submitting a 510(k)
and then a request for classification, if the person determines that
there is no legally marketed device upon which to base a determination
of substantial equivalence, that person requests a classification under
section 513(f)(2) of the FD&C Act.
Under either procedure for De Novo classification, FDA is required
to classify the device by written order within 120 days. The
classification will be according to the criteria under section
513(a)(1) of the FD&C Act. Although the device was automatically placed
within class III, the De Novo classification is considered to be the
initial classification of the device.
When FDA classifies a device into class I or II via the De Novo
process, the device can serve as a predicate for future devices of that
type, including for 510(k)s (see section 513(f)(2)(B)(i) of the FD&C
Act). As a result, other device sponsors do not have to submit a De
Novo request or premarket approval application to market a
substantially equivalent device (see section 513(i) of the FD&C Act,
defining ``substantial equivalence''). Instead, sponsors can use the
less-burdensome 510(k) process, when necessary, to market their device.
II. De Novo Classification
On December 13, 2018, FDA received Woven Orthopedic Technologies,
LLC's request for De Novo classification of the OGmend[supreg] Implant
System. FDA reviewed the request in order to classify the device under
the criteria for classification set forth in section 513(a)(1) of the
FD&C Act.
We classify devices into class II if general controls by themselves
are insufficient to provide reasonable assurance of safety and
effectiveness, but there is sufficient information to establish special
controls that, in combination with the general controls, provide
reasonable assurance of the safety and effectiveness of the device for
its intended use (see 21 U.S.C. 360c(a)(1)(B)). After review of the
information submitted in the request, we determined that the device can
be classified into class II with the establishment of special controls.
FDA has determined that these special controls, in addition to the
general controls, will provide reasonable assurance of the safety and
effectiveness of the device.
Therefore, on May 1, 2020, FDA issued an order to the requester
classifying the device into class II. In this final order, FDA is
codifying the classification of the device by adding 21 CFR
888.3043.\1\ We have named the generic type of device ``screw sleeve
bone fixation device,'' and it is intended to be implanted in
conjunction with a non-resorbable, metallic bone screw where the screw
has lost purchase due to loosening, backout, or breakage. The device
fits between the screw threads and surrounding bone and provides
increased surface area to create an
[[Page 11294]]
interference fit to restore stability of the implant construct.
---------------------------------------------------------------------------
\1\ FDA notes that the ``ACTION'' caption for this final order
is styled as ``Final amendment; final order,'' rather than ``Final
order.'' Beginning in December 2019, this editorial change was made
to indicate that the document ``amends'' the Code of Federal
Regulations. The change was made in accordance with the Office of
Federal Register's (OFR) interpretations of the Federal Register Act
(44 U.S.C. chapter 15), its implementing regulations (1 CFR 5.9 and
parts 21 and 22), and the Document Drafting Handbook.
---------------------------------------------------------------------------
FDA has identified the following risks to health associated
specifically with this type of device and the measures required to
mitigate these risks in table 1.
Table 1--Screw Sleeve Bone Fixation Device Risks and Mitigation Measures
------------------------------------------------------------------------
Identified risks Mitigation measures
------------------------------------------------------------------------
Loss of function/mechanical integrity In vivo performance testing;
resulting from: Non-clinical performance
[ssquf] Device malposition. testing; Shelf life testing;
[ssquf] Device breakage. and Labeling.
[ssquf] Damage to screw during
insertion.
[ssquf] Deterioration due to aging.
[ssquf] Insufficient restoration of
screw fixation.
Revision............................... In vivo performance testing;
Non-clinical performance
testing; and Labeling.
Adverse tissue reaction................ Biocompatibility evaluation; In
vivo performance testing; Non-
clinical performance testing;
and Labeling.
Infection.............................. Sterilization validation; and
Shelf life testing.
Febrile response due to endotoxins..... Pyrogenicity testing.
------------------------------------------------------------------------
FDA has determined that special controls, in combination with the
general controls, address these risks to health and provide reasonable
assurance of safety and effectiveness. For a device to fall within this
classification, and thus avoid automatic classification in class III,
it would have to comply with the special controls named in this final
order. The necessary special controls appear in the regulation codified
by this order. We encourage sponsors to consult with us if they wish to
use a non-animal testing method that they believe is suitable,
adequate, validated, and feasible. We will consider if such an
alternative method could be assessed for equivalency to an animal test
method. This device is subject to premarket notification requirements
under section 510(k) of the FD&C Act.
III. Analysis of Environmental Impact
The Agency has determined under 21 CFR 25.34(b) that this action is
of a type that does not individually or cumulatively have a significant
effect on the human environment. Therefore, neither an environmental
assessment nor an environmental impact statement is required.
IV. Paperwork Reduction Act of 1995
This final order establishes special controls that refer to
previously approved collections of information found in other FDA
regulations and guidance. These collections of information are subject
to review by the Office of Management and Budget (OMB) under the
Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3521). The collections
of information in 21 CFR part 860, subpart D, regarding De Novo
classification have been approved under OMB control number 0910-0844;
the collections of information in 21 CFR part 814, subparts A through
E, regarding premarket approval, have been approved under OMB control
number 0910-0231; the collections of information in part 807, subpart
E, regarding premarket notification submissions, have been approved
under OMB control number 0910-0120; the collections of information in
21 CFR part 820, regarding quality system regulation, have been
approved under OMB control number 0910-0073; and the collections of
information in 21 CFR part 801, regarding labeling, have been approved
under OMB control number 0910-0485.
List of Subjects in 21 CFR Part 888
Medical devices.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs, 21 CFR part
888 is amended as follows:
PART 888--ORTHOPEDIC DEVICES
0
1. The authority citation for part 888 continues to read as follows:
Authority: 21 U.S.C. 351, 360, 360c, 360e, 360j, 360l, 371.
0
2. Add Sec. 888.3043 to subpart D to read as follows:
Sec. 888.3043 Screw sleeve bone fixation device.
(a) Identification. A screw sleeve bone fixation device is intended
to be implanted in conjunction with a non-resorbable, metallic bone
screw where the screw has lost purchase due to loosening, backout, or
breakage. The device fits between the screw threads and surrounding
bone and provides increased surface area to create an interference fit
to restore stability of the implant construct.
(b) Classification. Class II (special controls). The special
controls for this device are:
(1) In vivo performance testing under anticipated conditions of use
must demonstrate:
(i) The device provides sufficient stability to allow for fracture
healing; and
(ii) A lack of adverse biologic response to the implant through
histopathological and histomorphometric assessment.
(2) Non-clinical performance testing must demonstrate that the
device performs as intended under anticipated conditions of use.
Testing must:
(i) Assess the stability of the device in a rescue screw scenario;
(ii) Demonstrate that the device can be inserted and removed
without damage to the implant or associated hardware;
(iii) Demonstrate the device can withstand dynamic loading without
device failure; and
(iv) Characterize wear particle generation.
(3) The device must be demonstrated to be biocompatible.
(4) The device must be demonstrated to be non-pyrogenic.
(5) Performance data must demonstrate the sterility of the device.
(6) Performance data must support the labeled shelf life of the
device by demonstrating continued sterility, package integrity, and
device functionality over the established shelf life.
(7) Labeling must include:
(i) A detailed summary of the device technical parameters;
(ii) Information describing all materials of the device;
(iii) Instructions for use, including device removal; and
(iv) A shelf life.
[[Page 11295]]
Dated: February 22, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-04154 Filed 2-28-22; 8:45 am]
BILLING CODE 4164-01-P